VAL (8) GLP-1 COMPOSITION AND METHOD FOR TREATING FUNCTIONAL DYSPEPSIA AND/OR IRRITABLE BOWEL SYNDROME
A method of treating functional dyspepsia and/or irritable bowel syndrome in mammals in need of treatment is disclosed herein. The method comprises administering to the mammal a formulation by inhalation, wherein the formulation avoids first pass metabolism of the active ingredient. The method compr...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | RICHARDSON, PETER KENNY, ENDA GRANT, MARSHALL, L DANIELS, SCOTT GREENE, STEPHANIE HELLSTROM, PER STOWELL, GRAYSON, W SMITHSON, ANTHONY |
| description | A method of treating functional dyspepsia and/or irritable bowel syndrome in mammals in need of treatment is disclosed herein. The method comprises administering to the mammal a formulation by inhalation, wherein the formulation avoids first pass metabolism of the active ingredient. The method comprises administering a formulation by pulmonary inhalation comprising a diketopiperazine and a glucagon-like peptide (GLP-1 ), analog, ROSE-010.
La présente invention concerne un procédé de traitement de la dyspepsie fonctionnelle et/ou du syndrome du côlon irritable chez des mammifères ayant besoin d'un tel traitement. Ledit procédé comprend l'administration, à un mammifère, d'une formulation par inhalation, ladite formulation évitant le métabolisme de premier passage de l'ingrédient actif. Ce procédé comprend plus précisément l'administration d'une formulation par inhalation pulmonaire qui comporte un dicétopipérazine et un ROSE-010 analogue du peptide semblable au glucagon (GLP-1). |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2011017554A3</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2011017554A3</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2011017554A33</originalsourceid><addsrcrecordid>eNqNy0ELgjAYgGEvHaL6Dx90qYPkUqnrdFMHc9_YVuJJJOYpSrD_Twr9gE7v5XnXwXCnEg7XI5RShwRyrDVa4QQqoIpBzV2FDAo04AynTqgSipvKFzCPrLWaayvogk8zEsYIRzPJIcOGS7CtYgZrvg1WQ_-c_O7XTbAvuMur0I_vzk9j__Av_-kaPEeEROSSpgmN4__UFyaNNX8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>VAL (8) GLP-1 COMPOSITION AND METHOD FOR TREATING FUNCTIONAL DYSPEPSIA AND/OR IRRITABLE BOWEL SYNDROME</title><source>esp@cenet</source><creator>RICHARDSON, PETER ; KENNY, ENDA ; GRANT, MARSHALL, L ; DANIELS, SCOTT ; GREENE, STEPHANIE ; HELLSTROM, PER ; STOWELL, GRAYSON, W ; SMITHSON, ANTHONY</creator><creatorcontrib>RICHARDSON, PETER ; KENNY, ENDA ; GRANT, MARSHALL, L ; DANIELS, SCOTT ; GREENE, STEPHANIE ; HELLSTROM, PER ; STOWELL, GRAYSON, W ; SMITHSON, ANTHONY</creatorcontrib><description>A method of treating functional dyspepsia and/or irritable bowel syndrome in mammals in need of treatment is disclosed herein. The method comprises administering to the mammal a formulation by inhalation, wherein the formulation avoids first pass metabolism of the active ingredient. The method comprises administering a formulation by pulmonary inhalation comprising a diketopiperazine and a glucagon-like peptide (GLP-1 ), analog, ROSE-010.
La présente invention concerne un procédé de traitement de la dyspepsie fonctionnelle et/ou du syndrome du côlon irritable chez des mammifères ayant besoin d'un tel traitement. Ledit procédé comprend l'administration, à un mammifère, d'une formulation par inhalation, ladite formulation évitant le métabolisme de premier passage de l'ingrédient actif. Ce procédé comprend plus précisément l'administration d'une formulation par inhalation pulmonaire qui comporte un dicétopipérazine et un ROSE-010 analogue du peptide semblable au glucagon (GLP-1).</description><language>eng ; fre</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2011</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20110623&DB=EPODOC&CC=WO&NR=2011017554A3$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,309,781,886,25569,76552</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20110623&DB=EPODOC&CC=WO&NR=2011017554A3$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>RICHARDSON, PETER</creatorcontrib><creatorcontrib>KENNY, ENDA</creatorcontrib><creatorcontrib>GRANT, MARSHALL, L</creatorcontrib><creatorcontrib>DANIELS, SCOTT</creatorcontrib><creatorcontrib>GREENE, STEPHANIE</creatorcontrib><creatorcontrib>HELLSTROM, PER</creatorcontrib><creatorcontrib>STOWELL, GRAYSON, W</creatorcontrib><creatorcontrib>SMITHSON, ANTHONY</creatorcontrib><title>VAL (8) GLP-1 COMPOSITION AND METHOD FOR TREATING FUNCTIONAL DYSPEPSIA AND/OR IRRITABLE BOWEL SYNDROME</title><description>A method of treating functional dyspepsia and/or irritable bowel syndrome in mammals in need of treatment is disclosed herein. The method comprises administering to the mammal a formulation by inhalation, wherein the formulation avoids first pass metabolism of the active ingredient. The method comprises administering a formulation by pulmonary inhalation comprising a diketopiperazine and a glucagon-like peptide (GLP-1 ), analog, ROSE-010.
La présente invention concerne un procédé de traitement de la dyspepsie fonctionnelle et/ou du syndrome du côlon irritable chez des mammifères ayant besoin d'un tel traitement. Ledit procédé comprend l'administration, à un mammifère, d'une formulation par inhalation, ladite formulation évitant le métabolisme de premier passage de l'ingrédient actif. Ce procédé comprend plus précisément l'administration d'une formulation par inhalation pulmonaire qui comporte un dicétopipérazine et un ROSE-010 analogue du peptide semblable au glucagon (GLP-1).</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2011</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNy0ELgjAYgGEvHaL6Dx90qYPkUqnrdFMHc9_YVuJJJOYpSrD_Twr9gE7v5XnXwXCnEg7XI5RShwRyrDVa4QQqoIpBzV2FDAo04AynTqgSipvKFzCPrLWaayvogk8zEsYIRzPJIcOGS7CtYgZrvg1WQ_-c_O7XTbAvuMur0I_vzk9j__Av_-kaPEeEROSSpgmN4__UFyaNNX8</recordid><startdate>20110623</startdate><enddate>20110623</enddate><creator>RICHARDSON, PETER</creator><creator>KENNY, ENDA</creator><creator>GRANT, MARSHALL, L</creator><creator>DANIELS, SCOTT</creator><creator>GREENE, STEPHANIE</creator><creator>HELLSTROM, PER</creator><creator>STOWELL, GRAYSON, W</creator><creator>SMITHSON, ANTHONY</creator><scope>EVB</scope></search><sort><creationdate>20110623</creationdate><title>VAL (8) GLP-1 COMPOSITION AND METHOD FOR TREATING FUNCTIONAL DYSPEPSIA AND/OR IRRITABLE BOWEL SYNDROME</title><author>RICHARDSON, PETER ; KENNY, ENDA ; GRANT, MARSHALL, L ; DANIELS, SCOTT ; GREENE, STEPHANIE ; HELLSTROM, PER ; STOWELL, GRAYSON, W ; SMITHSON, ANTHONY</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2011017554A33</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2011</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>RICHARDSON, PETER</creatorcontrib><creatorcontrib>KENNY, ENDA</creatorcontrib><creatorcontrib>GRANT, MARSHALL, L</creatorcontrib><creatorcontrib>DANIELS, SCOTT</creatorcontrib><creatorcontrib>GREENE, STEPHANIE</creatorcontrib><creatorcontrib>HELLSTROM, PER</creatorcontrib><creatorcontrib>STOWELL, GRAYSON, W</creatorcontrib><creatorcontrib>SMITHSON, ANTHONY</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>RICHARDSON, PETER</au><au>KENNY, ENDA</au><au>GRANT, MARSHALL, L</au><au>DANIELS, SCOTT</au><au>GREENE, STEPHANIE</au><au>HELLSTROM, PER</au><au>STOWELL, GRAYSON, W</au><au>SMITHSON, ANTHONY</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>VAL (8) GLP-1 COMPOSITION AND METHOD FOR TREATING FUNCTIONAL DYSPEPSIA AND/OR IRRITABLE BOWEL SYNDROME</title><date>2011-06-23</date><risdate>2011</risdate><abstract>A method of treating functional dyspepsia and/or irritable bowel syndrome in mammals in need of treatment is disclosed herein. The method comprises administering to the mammal a formulation by inhalation, wherein the formulation avoids first pass metabolism of the active ingredient. The method comprises administering a formulation by pulmonary inhalation comprising a diketopiperazine and a glucagon-like peptide (GLP-1 ), analog, ROSE-010.
La présente invention concerne un procédé de traitement de la dyspepsie fonctionnelle et/ou du syndrome du côlon irritable chez des mammifères ayant besoin d'un tel traitement. Ledit procédé comprend l'administration, à un mammifère, d'une formulation par inhalation, ladite formulation évitant le métabolisme de premier passage de l'ingrédient actif. Ce procédé comprend plus précisément l'administration d'une formulation par inhalation pulmonaire qui comporte un dicétopipérazine et un ROSE-010 analogue du peptide semblable au glucagon (GLP-1).</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_WO2011017554A3 |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | VAL (8) GLP-1 COMPOSITION AND METHOD FOR TREATING FUNCTIONAL DYSPEPSIA AND/OR IRRITABLE BOWEL SYNDROME |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T09%3A23%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=RICHARDSON,%20PETER&rft.date=2011-06-23&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2011017554A3%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |